StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30182% above fair value
$26.81−0.12 (-0.45%)

Close on Nov 20, 2026Market cap $1.73BP/E –Yield –

Stoke Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Stoke Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$180.68M, down 395.5% year over year. For fiscal 2025 it was $44.92M. The highest annual figure on record is $44.92M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.92M–
FY2024Dec 31, 2024-$87.05M–
FY2023Dec 31, 2023-$82.68M–
FY2022Dec 31, 2022-$35.83M–
FY2021Dec 31, 2021-$68.11M–
FY2020Dec 31, 2020-$43.27M–
FY2019Dec 31, 2019-$32.69M–
FY2018Dec 31, 2018-$11.90M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$58.56M–
Q1 FY2026Mar 31, 2026-$60.94M-146.3%
Q4 FY2025Dec 31, 2025-$30.69M–
Q3 FY2025Sep 30, 2025-$30.50M–
Q2 FY2025Jun 30, 2025-$25.58M–
Q1 FY2025Mar 31, 2025$131.68M–
Q4 FY2024Dec 31, 2024-$23.24M–
Q3 FY2024Sep 30, 2024-$21.72M–
Q2 FY2024Jun 30, 2024-$17.52M–
Q1 FY2024Mar 31, 2024-$24.58M–
Q4 FY2023Dec 31, 2023-$20.88M–
Q3 FY2023Sep 30, 2023-$17.65M–
Q2 FY2023Jun 30, 2023-$22.64M–
Q1 FY2023Mar 31, 2023-$21.52M-168.0%
Q4 FY2022Dec 31, 2022-$22.78M–
Q3 FY2022Sep 30, 2022-$24.09M–
Q2 FY2022Jun 30, 2022-$20.61M–
Q1 FY2022Mar 31, 2022$31.65M–
Q4 FY2021Dec 31, 2021-$16.46M–
Q3 FY2021Sep 30, 2021-$14.96M–
Q2 FY2021Jun 30, 2021-$16.35M–
Q1 FY2021Mar 31, 2021-$20.34M–
Q4 FY2020Dec 31, 2020-$11.02M–
Q3 FY2020Sep 30, 2020-$11.14M–
Q2 FY2020Jun 30, 2020-$9.73M–
Q1 FY2020Mar 31, 2020-$11.38M–
Q4 FY2019Dec 31, 2019-$10.77M–
Q3 FY2019Sep 30, 2019-$8.63M–
Q2 FY2019Jun 30, 2019-$6.67M–
Q1 FY2019Mar 31, 2019-$6.62M–
Q4 FY2018Dec 31, 2018-$3.61M–
Q3 FY2018Sep 30, 2018-$3.56M–

More Stoke Therapeutics figures

See a number that looks wrong?